Home Other Building Blocks 862189-95-5
862189-95-5,MFCD09954134
Catalog No.:AA00GU1I

862189-95-5 | Mirodenafil

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
95%
1 week  
$108.00   $76.00
- +
10mg
95%
1 week  
$140.00   $98.00
- +
25mg
95%
1 week  
$213.00   $149.00
- +
50mg
95%
1 week  
$311.00   $218.00
- +
100mg
95%
1 week  
$463.00   $324.00
- +
1g
99%
1 week  
$643.00   $450.00
- +
5g
99%
1 week  
$1,500.00   $1,050.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00GU1I
Chemical Name:
Mirodenafil
CAS Number:
862189-95-5
Molecular Formula:
C26H37N5O5S
Molecular Weight:
531.6675
MDL Number:
MFCD09954134
SMILES:
CCCOc1ccc(cc1c1[nH]c(=O)c2c(n1)c(CCC)cn2CC)S(=O)(=O)N1CCN(CC1)CCO
Properties
Computed Properties
 
Complexity:
902  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
37  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
11  
XLogP3:
2.2  

Literature

Title: Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.

Journal: Clinical therapeutics 20120901

Title: Validated LC-MS/MS method for the determination of mirodenafil in rat plasma and its application to a comparative pharmacokinetic study of the free base and hydrochloride salt forms of mirodenafil.

Journal: Arzneimittel-Forschung 20120701

Title: Analysis of prescriptions of alpha-blockers and phosphodiesterase 5 inhibitors from the urology department and other departments.

Journal: International neurourology journal 20111201

Title: cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

Journal: Current neuropharmacology 20111201

Title: Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetes.

Journal: International journal of andrology 20111001

Title: Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).

Journal: Expert opinion on therapeutic patents 20111001

Title: Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells.

Journal: Asian journal of andrology 20110901

Title: Prevalence and medical management of erectile dysfunction in Asia.

Journal: Asian journal of andrology 20110701

Title: The management of erectile dysfunction: innovations and future perspectives.

Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20110301

Title: Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, in spontaneously or DOCA-salt-induced hypertensive rats.

Journal: Biopharmaceutics & drug disposition 20110101

Title: Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.

Journal: International journal of impotence research 20110101

Title: Future prospects in the treatment of erectile dysfunction: focus on avanafil.

Journal: Drug design, development and therapy 20110101

Title: Crystal forms of SK-3530.

Journal: Archives of pharmacal research 20101201

Title: Efficacy and safety of mirodenafil in men taking antihypertensive medications.

Journal: The journal of sexual medicine 20100901

Title: Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study.

Journal: Korean journal of urology 20100901

Title: The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury.

Journal: International journal of impotence research 20100901

Title: Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Journal: The journal of sexual medicine 20100801

Title: Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats.

Journal: Xenobiotica; the fate of foreign compounds in biological systems 20100201

Title: Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541.

Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20100101

Title: The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.

Journal: Clinical therapeutics 20091201

Title: Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians.

Journal: Annals of internal medicine 20091103

Title: Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2.

Journal: The Journal of pharmacy and pharmacology 20091001

Title: Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats.

Journal: Biopharmaceutics & drug disposition 20090901

Title: Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea.

Journal: Clinical therapeutics 20090601

Title: Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats.

Journal: Journal of pharmaceutical and biomedical analysis 20090220

Title: Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.

Journal: The journal of sexual medicine 20081101

Title: The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury.

Journal: The Journal of veterinary medical science 20081101

Title: Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial.

Journal: Asian journal of andrology 20080901

Title: Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.

Journal: European urology 20080601

Title: Editorial comment on: chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.

Journal: European urology 20080601

Title: Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil.

Journal: Xenobiotica; the fate of foreign compounds in biological systems 20080101

Title: Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study.

Journal: Journal of pharmaceutical and biomedical analysis 20070921

Title: Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats.

Journal: Acta pharmacologica Sinica 20070801

Title: Formation of supramolecular hydrogels with controlled microstructures and stability via molecular assembling in a two-component system.

Journal: Journal of colloid and interface science 20070301

Title: Validation of a HPLC method for the quantification and purity determination of SK3530 in drug substance and tablet.

Journal: Journal of pharmaceutical and biomedical analysis 20070219

Title: Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats.

Journal: Rapid communications in mass spectrometry : RCM 20070101

Title: Paick, J.S., et al., Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med, 2008. 5(11): p. 2672-80.

Title: Kim, B.H., et al., Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther, 2009. 31(6): p. 1234-43.

Title: Shin, K.H., et al., The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther, 2009. 31(12): p. 3009-20.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 862189-95-5
Tags:862189-95-5 Molecular Formula|862189-95-5 MDL|862189-95-5 SMILES|862189-95-5 Mirodenafil